Multicenter trial validates continuous pregnancy-to-postpartum mobile health coaching programNovember 13, 2026
DNA methylation profiling stratifies recurrence risk in low-grade endometrial cancerNovember 13, 2026
General Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trialBy Healthcare Propulsion StaffNovember 10, 20260 Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and…
